Form 4: Veracyte SVP Annie McGuire Executes Stock Sale

Veracyte SVP and General Counsel Annie McGuire sold 10,204 shares of common stock via a pre-arranged 10b5-1 trading plan.

Summary

• Annie McGuire, SVP and General Counsel of Veracyte, Inc., sold a total of 10,204 shares of common stock on May 6, 2026.
• The shares were sold in two tranches: 5,102 shares at $38.05 and 5,102 shares at $40.00.
• Following these transactions, McGuire retains beneficial ownership of 143,708 shares of Veracyte common stock.
• The sales were executed pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was pre-planned and does not indicate a change in the company's strategic direction.

Positives

• The transaction was conducted under a pre-established Rule 10b5-1 plan, which is a standard mechanism for executives to sell shares without triggering insider trading concerns.

Negatives

• The sale represents a reduction in the executive's direct equity stake in the company.

Risks

• None identified in this filing.

Future Outlook

Not applicable as this is a routine disclosure of insider stock transactions.

Industry Context

StockSavvy.ai notes that routine 10b5-1 sales by executives are common in the biotechnology sector and generally do not signal a change in company fundamentals or management confidence.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate officers to manage personal liquidity while maintaining compliance with SEC regulations.

Stakeholder Impact

• Minimal impact on shareholders as the sale was executed via a pre-planned 10b5-1 arrangement.

Next Steps

• No future actions or milestones were mentioned in this filing.

Key Dates

Keywords

Veracyte, VCYT, Insider Trading, Form 4, Equity Sale, Rule 10b5-1